GLOBAL
PHARMACEUTICAL
COMPANY REPORT THE
PHARMA 1000
Ravneet Singh FC1008840
Contents Introduction:
BODY....
Conclusion:.
Introduction:
Torreya is a global active investment bank that focused on the pharmaceutical sector. There are many branches of pharmaceutical sector in which the Torreya has invested and in many countries, it has done extraordinary growth. In this report we got to know about many different sectors of pharma which are developing, and which are making great progress and the investments over the years. From 2003 to 2020 the progress pf pharma industry has been discussed in the report with the help of which we can find what we need to do to make it grow more rapidly.
BODY: As we know Torreya has done immense investment in pharma sector ... that is 30 ,000 companies since 2012. Large pharma has grown in mainly USA, Germany, China and in many other countries. The big growth area has been biologics, blood products and vaccines. As the pharma is doing great progress in these fields then company should focus in those areas of pharma, which is not developed as much like gene therapy, nucleic acid etc. More focus should also be given to those countries which have not shown any growth regarding pharma sector and the reasons need to be evaluated like why Japan and UK have not gained any substantial value yet. After 2015 many pharma companies fell out due to less investment or poor technology which need to be tackled so that many companies can grow. There are many regions in pharma like biotech, dermatology, branded pharma sector in gastroenterology, oncology etc. For biotech sector to be successful it needs access to human capital and innovation. Taiwan and Australia have shown great strength in biotech now. Commercial is important in the field of pharma and neurocrania and Sarepta both making strong commercial progress. As we read the report, we knew that INN generic sector has not performed that good in the past few years and these companies are losing their values. This might be due to financial issues. To run a pharma sector one need financial support and good investors. There is private equity in pharma sector and its percentage is 14%. For more growth of pharma sector royalty rate is important. Royalty rates can either be fixed of tiered. One should make sure the third-party license agreements you use are comparable. Duration of the license may also influence the royalty rates.